Featured Technology
ENGINEERING A SINGLE CHAIN ANTIBODY-BASED BIOLOGIC ARMED WTH AN APOPTOTIC EXECUTOR
Tumor specific antigens (TSAs) escape detection, thus allowing the tumor to grow unimpeded. The authors of this article propose that TSA targeted therapeutics are within reach and will be: (i) able to penetrate cells via a universal entry point; (ii) able to specifically bind to a TSA; and (iii) in response to the binding event trigger a cellular response,
preferably leading to the death of the tumor cell. From an engineering standpoint, the authors argue that this can
be accomplished by assembling three components in a logical way such that the detection of a Tumor Specific Antigen
within a cell leads to the induction of a desired downstream event; apoptosis.
PersonalizedMedicineTV.com
Featured Press Release
TriLink Enters into Distribution Agreement with Sigma-Aldrich
TriLink announced that it has entered into a distribution agreement with Sigma-Aldrich to sell its CleanAmp™ dNTPs globally.
Recent News
Dr. Richard Zhao, who is a Professor of Pathology, Microbiology-Immunology and Human Virology at the School of Medicine, University of Maryland Baltimore, discusses individualized molecular testing and personalized medicine in an interview with Alexander Kuklin, PhD at www.PersonalizedMedicineTV.com. He talks about Theragnostics, Prognomics, and Pharmacogenomics. (more)
Science Communicator and Rapper Oort Kuiper (the UK) discusses his song Genetics and his work as a song writer and performer at www.PersonalizedMedicineTV.com. (more)
bioteXcel consulting has recently been launched in the UK by it founder Elisabetta Fineschi. The company boasts a global footprint by having a team of professionals spanning China, India, Europe, US and Canada. This article discusses the beginning of bioteXcel and the visions of its founder. (more)
Genmab A/S (OMX: GEN) reports today that the last patient to be included in the planned interim analysis (N=132 patients) in the pivotal Phase III clinical trial of ofatumumab (HuMax-CD2) in refractory chronic lymphocytic leukemia (CLL) has now received the last scheduled treatment. (more)
infoQuant Ltd brings microarray technology closer to clinical use with its latest release of copy number analysis and interpretation software oneClickCGH and CGH Fusion for microarray-based comparative genomic hybridization tests (array CGH). (more)
Biotech Market Summary
| symbol | last price | date | time | change | open | high | low | volume |
|---|---|---|---|---|---|---|---|---|
| AFFY | 10.23 | 2/22/2012 | 3:03pm | -0.17 | 10.43 | 10.4425 | 10.05 | 820819 |
| ILMN | 50.86 | 2/22/2012 | 3:03pm | -0.59 | 51.11 | 51.64 | 50.56 | 2139420 |
| ARNA | 1.76 | 2/22/2012 | 3:03pm | -0.04 | 1.86 | 1.87 | 1.74 | 2920626 |
| VRUS | 0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| GENZ | 0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| A | 42.74 | 2/22/2012 | 3:04pm | +0.13 | 42.45 | 43.29 | 42.34 | 1658042 |
| MRK | 38.145 | 2/22/2012 | 3:04pm | +0.015 | 38.06 | 38.19 | 37.90 | 6717554 |